Targeting the right regulatory T-cell population for tumor immunotherapy
Regulatory T cells (Tregs) that suppress tumor-specific T cell-mediated immune responses are the subject of an intense wave of investigation. We recently reported that a subset of Tregs, namely effector/memory CD25low cells, are responsible for suppressing high avidity tumor-specific T cells in mous...
Main Authors: | Weiss, Vivian L., Lee, Timothy H., Jaffee, Elizabeth M., Armstrong, Todd D. |
---|---|
Format: | Online |
Language: | English |
Published: |
Landes Bioscience
2012
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494642/ |
Similar Items
-
Trafficking of High Avidity HER-2/neu-Specific T Cells into HER-2/neu-Expressing Tumors after Depletion of Effector/Memory-Like Regulatory T Cells
by: Weiss, Vivian L., et al.
Published: (2012) -
Regulatory T Cells as Immunotherapy
by: Singer, Benjamin D., et al.
Published: (2014) -
Myeloid-derived cells are key targets of tumor immunotherapy
by: Medina-Echeverz, José, et al.
Published: (2014) -
Small-Molecule Targets in Tumor Immunotherapy
by: Hui-Fang Zhu, et al.
Published: (2018-07-01) -
Antibody targeted CpG for the immunotherapy of solid tumors
by: Epstein, Alan L, et al.
Published: (2015)